Vir Biotechnology (VIR) Scheduled to Post Earnings on Thursday

Vir Biotechnology (NASDAQ:VIR) is scheduled to be releasing its earnings data after the market closes on Thursday, May 2nd. Analysts expect Vir Biotechnology to post earnings of ($0.99) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Vir Biotechnology (NASDAQ:VIR) last released its quarterly earnings data on Thursday, February 22nd. The company reported ($0.86) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.14) by $0.28. The company had revenue of $16.80 million for the quarter, compared to analyst estimates of $11.18 million. Vir Biotechnology had a negative return on equity of 34.92% and a negative net margin of 713.69%. The firm’s revenue for the quarter was down 66.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.76) earnings per share. On average, analysts expect Vir Biotechnology to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Vir Biotechnology Stock Performance

NASDAQ VIR opened at $8.46 on Wednesday. The stock’s fifty day moving average is $9.87 and its two-hundred day moving average is $9.59. The firm has a market capitalization of $1.14 billion, a P/E ratio of -1.84 and a beta of 0.41. Vir Biotechnology has a fifty-two week low of $7.61 and a fifty-two week high of $27.48.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on VIR shares. JPMorgan Chase & Co. boosted their price objective on Vir Biotechnology from $9.00 to $10.00 and gave the stock a “neutral” rating in a research note on Friday, February 23rd. HC Wainwright reissued a “buy” rating and set a $110.00 price objective on shares of Vir Biotechnology in a research note on Friday, March 15th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $34.38.

Insider Activity

In other news, Director George A. Scangos sold 10,878 shares of the company’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $10.24, for a total value of $111,390.72. Following the transaction, the director now owns 157,611 shares of the company’s stock, valued at approximately $1,613,936.64. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, EVP Phillip Pang sold 3,321 shares of the business’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $10.24, for a total value of $34,007.04. Following the sale, the executive vice president now owns 264,679 shares in the company, valued at approximately $2,710,312.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director George A. Scangos sold 10,878 shares of the business’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $10.24, for a total value of $111,390.72. Following the completion of the sale, the director now owns 157,611 shares in the company, valued at approximately $1,613,936.64. The disclosure for this sale can be found here. Insiders have sold a total of 152,831 shares of company stock valued at $1,525,844 in the last quarter. Insiders own 15.60% of the company’s stock.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand.